^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TCF7L2 mutation

    i
    Other names: TCF7L2, Transcription Factor 7 Like 2, Transcription Factor 7-Like 2 (T-Cell Specific HMG-Box), T-Cell-Specific Transcription Factor 4, HMG Box Transcription Factor 4, Transcription Factor 7-Like 2, T-Cell Factor 4, HTCF-4, TCF-4, TCF4
    Entrez ID:
    6934
    Related biomarkers:
    Expression
    CNA
    almost3years
    Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma. (PubMed, J Gastrointest Oncol)
    In this study, we investigated the comprehensive genomic characterizations of CCA patients, identified the significant alterations in each subtype, and identified potential biomarkers for prognosis prediction. These results provide molecular evidence for the heterogeneity of CCA subtypes and evidence for further precision targeted therapy of CCA patients.
    Journal • Tumor Mutational Burden
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • FGFR2 (Fibroblast growth factor receptor 2) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase) • MDM2 (E3 ubiquitin protein ligase) • SMAD4 (SMAD family member 4) • KDM6A (Lysine Demethylase 6A) • ARID2 (AT-Rich Interaction Domain 2) • FAT4 (FAT Atypical Cadherin 4) • TCF7L2 (Transcription Factor 7 Like 2) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4)
    |
    TP53 mutation • KRAS mutation • PIK3CA mutation • HER-2 mutation • ARID1A mutation • FGFR2 mutation • NF1 mutation • KDM6A mutation • TP53 mutation + KRAS mutation • TERT mutation • MDM2 mutation • TCF7L2 mutation
    almost3years
    Genetic Alteration Profiling of Chinese Lung Adenocarcinoma and Its Effect on Targeted Therapy Efficacy. (PubMed, Front Oncol)
    LUAD patients from eastern China have a unique profile of mutations. The targeted DNA panel is helpful for personalized treatment decision of LUAD patients, and specific mutations may affect the efficacy of targeted therapies.
    Clinical • Journal • Tumor Mutational Burden
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • RB1 (RB Transcriptional Corepressor 1) • ATR (Ataxia telangiectasia and Rad3-related protein) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • SPTA1 (Spectrin Alpha) • TCF7L2 (Transcription Factor 7 Like 2) • TYK2 (Tyrosine Kinase 2)
    |
    TP53 mutation • EGFR mutation • HER-2 mutation • CEBPA mutation • TCF7L2 mutation
    4years
    TCF 4 tumor suppressor: a molecular target in the prognosis of sporadic colorectal cancer in humans. (PubMed, Cell Mol Biol Lett)
    Hence the alterations in genomic architecture along with downregulation of TCF-4 mRNA and decreased expression of TCF-4 protein in tumors, which is in accordance with clinical features, suggest its involvement in the pathogenesis of CRC. Thus, deregulation and collaboration of TCF-4 with CRC could be a concrete and distinctive feature in the prognosis of the disease at an early stage of development.
    Journal
    |
    TCF7L2 (Transcription Factor 7 Like 2)
    |
    TCF7L2 mutation